Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome

The 2022 Option Agreement between Astellas and Taysha has expiredRegaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus ...